Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Endeavour Silver Corp (EXK) vs Novo Nordisk A/S (NVO) Price & Performance

Endeavour Silver CorpTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Endeavour Silver Corp vs Novo Nordisk A/S — how do they compare? Endeavour Silver Corp trades at $10.68 (market cap $3.14B), while Novo Nordisk A/S trades at $46.18 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 66.2× Endeavour Silver Corp's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.

EXKNVO
Market Cap
$3.14B$207.85B
Sector
Basic MaterialsHealth
52-Week High
$14.12$63.98
52-Week Low
$5.31$35.29
Enterprise Value
$3.14B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Endeavour Silver Corp

Endeavour Silver (EXK) trades at $10.60, up 3.52% today, with strong technical momentum and bullish analyst sentiment. The company shows improving fundamentals with Q1 2026 earnings beating expectations and revenue growth projected from $468M in 2025 to $737M in 2026. Recent news highlights operational expansion, including the Terronera mine ramp-up and a new $25M credit facility, supporting future growth in silver and gold production.

Outlook is positive with 78.6% analyst buy ratings and a $15.50 consensus price target offering 46% upside. Key risks include execution of mine expansions, commodity price volatility, and the company's transition to profitability after a 2025 net loss. The stock presents a growth opportunity if operational targets are met, though investors should monitor quarterly earnings consistency.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Endeavour Silver Corp

Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.

Read more on EXK

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO